Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.86 USD
+0.02 (2.41%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $0.85 -0.01 (-1.16%) 6:26 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Lucid Diagnostics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 19 | 22 | 54 | 0 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 2 | 3 | 1 | NA |
Total Current Assets | 22 | 24 | 57 | 1 | NA |
Net Property & Equipment | 1 | 2 | 1 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 1 | 3 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 1 | 1 | 1 | NA |
Total Assets | 27 | 33 | 59 | 2 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 1 | 1 | 1 | 2 | NA |
Current Portion Long-Term Debt | 14 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 4 | 1 | 1 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 9 | 5 | 2 | 13 | NA |
Total Current Liabilities | 29 | 8 | 4 | 16 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 30 | 9 | 4 | 16 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 19 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 130 | 121 | 97 | 0 | NA |
Retained Earnings | -151 | -98 | -42 | -14 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | -2 | 23 | 55 | -14 | NA |
Total Liabilities & Shareholder's Equity | 27 | 33 | 59 | 2 | NA |
Total Common Equity | -21 | 23 | 55 | -14 | 0 |
Shares Outstanding | 44.60 | 39.10 | 36.80 | NA | NA |
Book Value Per Share | -0.47 | 0.59 | 1.49 | 0.00 | 0.00 |
Fiscal Year End for Lucid Diagnostics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 25 | 19 | 24 | 33 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 3 | 3 | 3 |
Total Current Assets | NA | 28 | 22 | 27 | 36 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 2 | 2 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 32 | 27 | 33 | 42 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 13 | 14 | 14 | 12 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 4 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 9 | 10 | 11 |
Total Current Liabilities | NA | 20 | 29 | 30 | 27 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 20 | 30 | 31 | 27 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 44 | 19 | 14 | 14 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 136 | 130 | 129 | 127 |
Retained Earnings | NA | -169 | -151 | -140 | -126 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | -2 | 3 | 15 |
Total Liabilities & Shareholder's Equity | NA | 32 | 27 | 33 | 42 |
Total Common Equity | 0 | -32 | -21 | -11 | 1 |
Shares Outstanding | 52.40 | 49.70 | 44.60 | 43.30 | 43.30 |
Book Value Per Share | 0.00 | -0.65 | -0.47 | -0.26 | 0.03 |